Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: From 10Q on Holocom page 16 -some may have seen this

From 10Q on Holocom page 16 -some may have seen this

posted on Feb 19, 2007 03:15PM
At the time of this filing, the Company was in negotiations with representatives of the management and the investors of Holocom Networks that were expected to lead to the conversion of the Company’s cash advances under the line of credit to an equity investment in a reorganized Holocom entity. Further advances in connection with the Holocom investment are anticipated. The Company is accounting for its investment in debt at cost. The Company monitors the value of its investment in debt for indicators of impairment, including changes in market conditions and /or the operating results of its underlying investment that may result in the inability to recover the carrying value of the investment. The Company will record an impairment charge if and when it believes the investment has experienced a decline that is other than temporary. At November 30, 2006, the Company has determined that there is no impairment of its investment in debt securities.
 
Share
New Message
Please login to post a reply